收稿日期: 2022-06-27
网络出版日期: 2022-10-14
柯杨 , 王敏敏 , 刘萌飞 , 刘芳芳 , 刘英 , 何忠虎 . 肿瘤早期预警生物标志物的研究与思考[J]. 北京大学学报（医学版）, 2022 , 54(5) : 810 -813 . DOI: 10.19723/j.issn.1671-167X.2022.05.005
| 1 | Arya SK , Bhansali S . Lung cancer and its early detection using biomarker-based biosensors[J]. Chem Rev, 2011, 111 (11): 6783- 6809. |
| 2 | Li W , Li C , Zhou T , et al. Role of exosomal proteins in cancer diagnosis[J]. Mol Cancer, 2017, 16 (1): 145. |
| 3 | Seijo LM , Peled N , Ajona D , et al. Biomarkers in lung cancer screening: achievements, promises, and challenges[J]. J Thorac Oncol, 2019, 14 (3): 343- 357. |
| 4 | Li L , Choi JY , Lee KM , et al. DNA methylation in peripheral blood: A potential biomarker for cancer molecular epidemiology[J]. J Epidemiol, 2012, 22 (5): 384- 394. |
| 5 | Anindo MI , Yaqinuddin A . Insights into the potential use of microRNAs as biomarker in cancer[J]. Int J Surg, 2012, 10 (9): 443- 449. |
| 6 | Issaq HJ , Fox SD , Chan KC , et al. Global proteomics and metabolomics in cancer biomarker discovery[J]. J Sep Sci, 2011, 34 (24): 3484- 3492. |
| 7 | Goto M , Liu M . Chemokines and their receptors as biomarkers in esophageal cancer[J]. Esophagus, 2020, 17 (2): 113- 121. |
| 8 | Yazbeck R , Jaenisch SE , Watson DI . From blood to breath: New horizons for esophageal cancer biomarkers[J]. World J Gastroenterol, 2016, 22 (46): 10077- 10083. |
| 9 | Sharma P , Sharma R . miRNA-mRNA crosstalk in esophageal cancer: From diagnosis to therapy[J]. Crit Rev Oncol Hematol, 2015, 96 (3): 449- 462. |
| 10 | Hayes DF . Defining clinical utility of tumor biomarker tests: A clinician's viewpoint[J]. J Clin Oncol, 2021, 39 (3): 238- 248. |
| 11 | Oon SF , Pennington SR , Fitzpatrick JM , et al. Biomarker research in prostate cancer: Towards utility, not futility[J]. Nat Rev Urol, 2011, 8 (3): 131- 138. |
| 12 | Kern SE . Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures[J]. Cancer Res, 2012, 72 (23): 6097- 6101. |
| 13 | Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem[J/OL]. BMC Med, 2012, 10: 87(2012-08-09)[2022-06-01]. https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-10-87. |
| 14 | He Z , Liu Z , Liu M , et al. Efficacy of endoscopic screening for esophageal cancer in China (ESECC): Design and preliminary results of a population-based randomised controlled trial[J]. Gut, 2019, 68 (2): 198- 206. |
| 15 | Liu F , Guo F , Zhou Y , et al. The anyang esophageal cancer cohort study: Study design, implementation of fieldwork, and use of computer-aided survey system[J]. PLoS One, 2012, 7 (2): e31602. |
| 16 | Wang M, Liu F, Pan Y, et al. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk[J/OL]. Ebiomedicine, 2021, 73: 103674[2022-06-01]. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00468-0/fulltext. |
| 17 | Liu M, Liu Y, Zhou R, et al. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions[J/OL]. J Pathol, 2022(2022-05-25)[2022-06-01]. https://onlinelibrary.wiley.com/doi/10.1002/path.5970. |
| 18 | Liu F , Liu M , Liu Y , et al. Oral microbiome and risk of malignant esophageal lesions in a high-risk area of China: A nested case-control study[J]. Chin J Cancer Res, 2020, 32 (6): 742- 754. |
| 19 | Zeng H , Ran X , An L , et al. Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6 (12): e877- e887. |
| 20 | Chen H, Knebel P, Brenner H. Empirical evaluation demonstrated importance of validating biomarkers for early detection of cancer in screening settings to limit the number of false-positive findings[J/OL]. J Clin Epidemiol, 2016, 75: 108-114[2022-06-01]. https://www.jclinepi.com/article/S0895-4356(16)00059-7/fulltext. |
/
| 〈 |
|
〉 |
